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Antimicrobials are commonly prescribed and contrib-
ute to the development of antimicrobial resistance in 
long-term care facilities (LTCFs). In 2010, the European 
Centre for Disease Prevention and Control initiated 
point prevalence surveys (PPS) of healthcare-asso-
ciated infections and antimicrobial use in European 
LTCFs, performed by external contractors as the 
Healthcare-Associated infections in Long-Term care 
facilities (HALT) projects. Here, we investigated preva-
lence and characteristics of antimicrobial use and anti-
microbial stewardship indicators in European LTCFs 
in 2016–17. Twenty-four European Union/European 
Economic Area (EU/EEA) countries, the former Yugoslav 
Republic of Macedonia and Serbia participated in the 
third PPS in European LTCFs. Overall, 4.9% (95% con-
fidence interval: 4.8–5.1) of LTCF residents in the EU/
EEA participating countries received at least one anti-
microbial. The most commonly reported Anatomical 
Therapeutic Chemical (ATC) groups were beta-lactam 
antibacterials/penicillins (J01C), other antibacterials 
(J01X) (e.g. glycopeptide antibacterials, polymyxins), 
quinolones (J01M), sulfonamides and trimethoprim 
(J01E), and other beta-lactams (J01D). Urinary tract 
infections and respiratory tract infections were the 
main indications for antimicrobial prescription. This 
PPS provides updated and detailed information on 
antimicrobial use in LTCFs across the EU/EEA that can 
be used to identify targets for future interventions, 
follow-up of these interventions and promote prudent 
use of antimicrobials in European LTCFs.
Introduction
Life expectancy is increasing steadily in the European 
Union/European Economic Area (EU/EEA). Population 
projections estimate that by 2050 the old-age depend-
ency ratio, calculated as the number of individuals 
aged over 65 years per 100 people of working age, will 
reach 50% [1]. The ageing population is one reason for 
the transitions in healthcare delivery systems taking 
place in several EU/EEA countries. This includes reduc-
tions in hospital beds and in several countries more 
patient care being provided in long-term care settings 
[2]. Long-term care facilities (LTCFs) deliver a blend of 
health and social services to people who are limited in 
their ability to live independently, especially due to old 
age, and are in need of less intensive medical care than 
that usually provided in hospitals [3].
Despite the fact that less intensive medical care is 
provided in LTCFs than in hospitals, healthcare-asso-
ciated infections (HAIs) are common in the vulnerable 
LTCF populations [4-9]. For this reason, antimicrobials 
are commonly prescribed in LTCFs, contributing to the 
development of antimicrobial resistance (AMR) and 
possibly leading to adverse events such as Clostridium 
difficile infection, and infections that are more difficult 
to treat [10,11]. As there is increasing evidence that 
LTCFs can serve as a reservoir for the transmission 
of resistant organisms to other healthcare settings, 
close monitoring of the situation is needed [12,13]. 
Furthermore, the lack of diagnostic capabilities may 
lead to suboptimal antimicrobial prescription in LTCFs 
[14,15].
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Data on antimicrobial use in LTCFs are necessary to 
understand the reasons, magnitude and determinants 
of antimicrobial prescribing and to inform public health 
policies on prudent use of antimicrobials. In June 2017, 
the European Commission published guidelines for 
the prudent use of antimicrobials in human medicine, 
recommending to establish antimicrobial stewardship 
programmes in all healthcare facilities, including LTCFs 
[16]. Although several European countries already 
measure antimicrobial consumption, methodologies 
have not been consistent precluding meaningful com-
parisons, furthermore they have often concentrated in 
the acute care settings, with little attention given to 
LTCFs.
For this reason, the European Centre for Disease 
Prevention and Control (ECDC) initiated surveillance 
of HAIs and antimicrobial use in European LTCFs with 
point prevalence surveys (PPSs) under the Healthcare-
Associated infections in Long-Term Care facilities 
(HALT) projects in 2010, 2013 and, most recently, in 
2016–17. In the present study, we investigated the 
prevalence and characteristics of antimicrobial use and 
antimicrobial stewardship indicators in European LTCFs 
reported in the third European PPS of HAIs and antimi-
crobial use in LTCFs (HALT-3) in 2016–17.
Table 1
Prevalence of antimicrobial use, by country, 23 European Union/European Economic Area countriesa, the former Yugoslav 
Republic of Macedonia and Serbia, 2016–2017
Country
LTCFs Eligible residents
Antimicrobial use
Residents with 
at least one 
antimicrobial
Observed 
prevalence
Mean 
prevalence of 
LTCFs
Median 
prevalence of 
LTCFs
n n n % (95% CI) % IQR (%)
Austria 12 2,065 67 3.2 (2.5 to 4.1) 2.9 2.4 (1.0 to 4.7)
Belgium 79 8,206 482 5.9 (5.4 to 6.4) 5.8 5.1 (2.9 to 8.1)
Croatia 8 1,607 32 2.0 (1.4 to 2.8) 3.2 3.6 (0.8 to 4.9)
Cyprus 11 312 29 9.3 (6.3 to 13.1) 10.1 7.7 (4.8 to 17.0)
Denmark 95 3,346 350 10.5 (9.4 to 11.5) 10.7 9.0 (6.3 to 15.0)
Finland 149 5,914 394 6.7 (6.0 to 7.3) 7.0 5.9 (2.3 to 10.5)
France 91 6,957 187 2.7 (2.3 to 3.1) 2.7 2.3 (0 to 4.3)
Germany 82 6,705 85 1.3 (1.0 to 1.6) 1.3 0.9 (0 to 1.9)
Greece 13 812 49 6.0 (4.5 to 7.9) 7.5 4.2 (3.0 to 11.6)
Hungary 75 7,670 71 0.9 (0.7 to 1.2) 0.9 0 (0 to 1.4)
Ireland 109 5,613 543 9.7 (8.9 to 10.5) 11.7 8.6 (5.4 to 14.7)
Italy 196 11,417 495 4.3 (4.0 to 4.7) 5.5 3.1 (0.8 to 6.6)
Lithuania 26 3,438 25 0.7 (0.5 to 1.1) 0.9 0 (0 to 1.0)
Luxembourg 16 1,616 42 2.6 (1.9 to 3.5) 2.5 1.5 (0.9 to 4.2)
Malta 11 2,485 66 2.7 (2.1 to 3.4) 1.6 1.4 (0.5 to 2.4)
The Netherlands 57 4,547 202 4.4 (3.9 to 5.1) 5.1 4.3 (1.6 to 6.7)
Norway 62 2,447 169 6.9 (5.9 to 8.0) 7.0 4.6 (2.1 to 10.3)
Poland 24 2,281 73 3.2 (2.5 to 4.0) 4.4 2.9 (0.9 to 6.5)
Portugal 132 3,633 220 6.1 (5.3 to 6.9) 6.8 4.3 (0 to 10.0)
Slovakia 59 5,091 113 2.2 (1.8 to 2.7) 2.9 1.2 (0 to 3.4)
Spain 46 6,808 717 10.5 (9.8 to 11.3) 11.7 10.8 (3.5 to 17.3)
Sweden 285 3,604 118 3.3 (2.7 to 3.9) 3.2 0 (0 to 5.6)
UK – Northern Ireland 70 2,614 270 10.3 (9.2 to 11.6) 10.4 9.8 (5.0 to 14.3)
UK – Scotland 52 2,147 138 6.4 (5.4 to 7.5) 6.2 5.1 (0 to 10.9)
UK – Wales 28 966 98 10.1 (8.3 to 12.2) 10.1 8.2 (5.5 to 11.4)
EU/EEA 1,788 102,301 5,035 4.9 (4.8 to 5.1) 5.8 3.6 (0 to 8.5)
former Yugoslav Republic 
of Macedonia 4 294 26 8.8 (5.9 to 12.7) 5.2 5.1 (2.5 to 7.9)
Serbia 6 1,168 57 4.9 (3.7 to 6.3) 6.0 4.0 (3.7 to 5.5)
CI: confidence interval; EU/EEA: European Union/European Economic Area; IQR: interquartile range; LTCFs: long-term care facilities; UK: United 
Kingdom.
aFor the United Kingdom, data for Northern Ireland, Scotland and Wales are presented separately. England did not participate in the survey. 
The Czech Republic did not provide resident-level data.
3www.eurosurveillance.org
Figure 1
Indications (treatment or prophylaxis, for the most commonly sites of infection) for antimicrobial use in long-term care 
facilities, by country, 22 European Union/European Economic Area countriesa, the former Yugoslav Republic of Macedonia 
and Serbia, 2016–2017
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EU/EEA: European Union/European Economic Area.
aFor the United Kingdom, data for Northern Ireland, Scotland and Wales are presented separately. England did not participate in the survey. 
The Czech Republic did not provide resident-level data. Cyprus did not provide detailed information on antimicrobial prescribing.
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Methods
Survey design
The survey was performed in 24 EU/EEA countries 
and two EU candidate countries, the former Yugoslav 
Republic of Macedonia and Serbia. The countries were 
asked to recruit LTCFs in their country for participa-
tion in the survey. According to the protocol [17], the 
selected LTCFs had to provide a broad range of ser-
vices and assistance to people with limited abilities to 
function independently on a daily basis (i.e. to autono-
mously perform the basic activities of daily living over 
an extended period of time). In addition, these LTCFs 
could also provide basic medical services (wound 
dressing, pain management, medication, health moni-
toring, prevention, rehabilitation or palliative care), but 
the LTCF residents had to be medically stable, without 
the need for constant specialised medical care or inva-
sive medical procedures. Resident stay in the selected 
Figure 2
Distribution of antibacterials for systemic use (ATC group J01) into groups, by main indication (prophylaxis or treatment) 
and by country, 22 European Union/European Economic Area countriesa, the former Yugoslav Republic of Macedonia and 
Serbia, 2016–2017
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The Czech Republic did not provide resident-level data. Cyprus did not provide detailed information on antimicrobial prescribing.
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LTCFs could vary from temporary to permanent (until 
end of life).
To improve country representativeness, a recom-
mended minimum number of LTCFs per country was 
calculated and provided to the national coordinators. 
For each country, the recommended sample size was 
calculated anticipating a national crude HAI prevalence 
of 4%, with a 95% confidence interval (CI) of 3–5% 
(1% precision). Although representative sampling was 
strongly recommended, purposive sampling, including 
convenience sampling or voluntary participation after 
the invitation of all LTCFs, was also accepted. Different 
types of LTCF could be recruited. While also specialised 
LTCF types (such as psychiatric facilities, rehabilita-
tion centres and palliative care centres) were invited 
to participate, only data from general nursing homes 
(providing principally care to seniors with severe ill-
nesses or injuries), residential homes (facilities usu-
ally providing personal care, housekeeping and three 
meals a day) and mixed LTCFs (providing mixed ser-
vices for elderly or other resident populations) were 
considered for analysis. For countries contributing to 
the survey with more residents than in the calculated 
recommended sample size, a randomised sub-sample 
was used in the final analysis [17].
Data collection
Participating countries were asked to organise the sur-
vey during one of four proposed periods: April–June 
or September–November in 2016 or 2017. Ideally, data 
had to be collected on a single day for each LTCF. In 
large LTCFs, data collection could take place over 2 or 
more consecutive days, but all residents within one 
ward or unit had to be surveyed on the same day.
Data collection was conducted either by an external 
data collector (i.e. the national coordinator or a person 
trained by the national coordinator) or by a local data 
collector (i.e. an LTCF staff member, e.g. designated 
physician, infection control practitioner or nurse). To 
ensure standardisation of data collection, a ‘train-
the-trainers’ workshop for the national coordinators 
was held in December 2015. It was recommended that 
national coordinators organise at least one 1-day infor-
mation and training session for the LTCFs before the 
national survey [17].
A resident questionnaire was used to collect data for 
each resident receiving a systemic antimicrobial on 
the day of the survey. Data included resident charac-
teristics (age, gender, length of stay in the LTCF (less 
or greater than 1 year)), risk factors (urinary catheter, 
vascular catheter, pressure sores, other wounds), care 
load indicators (faecal and/or urinary incontinence, 
disorientation in time and/or space, impaired mobility) 
and antimicrobial use (name of antimicrobial agent(s), 
indication and reasons for antimicrobial use, place of 
prescription, administration route, end or review date 
of documented prophylaxis or treatment) [17].
The 2018 version of the Anatomical Therapeutic 
Chemical/Defined Daily Dose (ATC/DDD) Index of the 
World Health Organization Collaborating Centre for 
Drug Statistics Methodology was used to classify the 
antimicrobials into different groups [18]. Antimicrobial 
agents for systemic use within ATC groups A07AA (intes-
tinal antiinfectives), D01BA (dermatological antifungals 
for systemic use), J01 (antibacterials for systemic use), 
J02 (antimycotics for systemic use), J04 (antimyco-
bacterials), when used for treatment of mycobacteria 
(including tuberculosis) or as reserve for multidrug-
resistant bacteria and P01AB (nitroimidazole-derived 
antiprotozoals), were included. Antiviral agents were 
not included.
Two main indications for antimicrobial use were 
recorded, i.e. prophylaxis and treatment. The indication 
Table 2
Multivariable linear regression analysis of long-term 
care facility and resident characteristics in relation to 
the prevalence of antimicrobial use, 19 European Union/
European Economic Area countriesa, the former Yugoslav 
Republic of Macedonia and Serbia, 2016–2017
Characteristics
Coefficient  
 
(95% CI)
p-value
Type of LTCF
Residential home Ref
General nursing home 0.38 (-0.54 to 1.31) 0.418
Mixed 1.41 (0.40 to 2.42) 0.006
Size of LTCF
≥ 105 beds Ref
65–104 beds 0.62 (-0.47 to 1.71) 0.266
37–64 beds 2.25 (1.22 to 3.29)   < 0.001
< 37 beds 3.27 (2.25 to 4.29)   < 0.001
Characteristics of LTCF residents (%)
Aged over 85 years 0.05 (0.03 to 0.08)   < 0.001
Male 0.08 (0.05 to 0.11)   < 0.001
Using a wheelchair or 
bedridden -0.04 (-0.06 to -0.02)   < 0.001
Disoriented in time and/or 
space 0.00 (-0.01 to 0.02) 0.648
Urinary and/or faecal 
incontinence 0.02 (-0.00 to 0.04) 0.052
Pressure sore -0.03 (-0.09 to 0.02) 0.229
Other wound 0.10 (0.06 to 0.14)   < 0.001
Surgery in the previous 30 
days 0.20 (0.10 to 0.30)   < 0.001
Urinary catheter 0.04 (0.00 to 0.08) 0.043
Vascular catheter 0.26 (0.18 to 0.33)   < 0.001
CI: confidence interval; EU/EEA: European Union/European 
Economic Area; LTCF: long-term care facility.
aFor the United Kingdom, data for Northern Ireland, Scotland and 
Wales were reported separately. England did not participate in 
the survey. The Czech Republic did not provide resident-level 
data. France, Portugal, Norway and Sweden were excluded from 
the multivariable analysis (see Methods).
Significant p-values are shown in bold.
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was further divided according to the anatomical site or 
diagnosis of prophylaxis or treatment: urinary tract, 
genital tract, skin or wound, respiratory tract, gastroin-
testinal tract, eye, ear-nose-mouth, surgical site, tuber-
culosis, systemic infection, unexplained fever or other 
site or diagnosis not previously specified.
An LTCF institutional questionnaire was used to col-
lect data on structures and processes in place in each 
participating LTCF, including current infection control 
practices and antimicrobial policies, e.g. written guide-
lines for appropriate antimicrobial use in the facility, 
annual regular training on appropriate antimicrobial 
prescribing or a ‘restrictive list’ of antimicrobials to be 
prescribed. In addition, anonymised and aggregated 
denominator data were also collected for the entire 
eligible LTCF population and included information on 
gender distribution, as well as the proportion of resi-
dents aged over 85 years who were receiving at least 
one antimicrobial agent, were disoriented in time and/
or space, had urinary and/or faecal incontinence, had 
impaired mobility, had pressure sores, had a urinary 
catheter, had a vascular catheter, had other wounds 
and/or had surgery in the previous 30 days.
Statistical analysis
All data were checked for errors, omissions and incon-
sistent answers on the national level and centrally 
before analysis.
Analyses were performed in SAS 9.3 (SAS Institute, 
Cary, NC, United States) and R 3.5.0 (R Foundation for 
Statistical Computing, Vienna, Austria). We calculated 
the crude, pooled prevalence of antimicrobial use as 
the number of residents receiving at least one antimi-
crobial agent divided by the total number of eligible 
residents on the day of the survey. We also calculated 
the mean, median and interquartile range (IQR) for the 
prevalence of antimicrobial use for the included LTCFs 
overall and within each country.
Multivariable linear regression was used to assess the 
association between antimicrobial use on the day of 
the survey and the type and size of LTCFs, as well as 
characteristics of the LTCF resident population, includ-
ing care load indicators. Countries reporting data by 
LTCF ward without indication of the corresponding LTCF 
(Portugal and Sweden), or data from LTCFs with miss-
ing population data on the LTCF questionnaire (France 
and Norway), as well as LTCFs which reported a prev-
alence of antimicrobial use of more than 60%, were 
excluded from this analysis. The latter were considered 
outliers and represented less than 0.2% of all partici-
pating LTCFs.
Ethical considerations and confidentiality
Each participating country had different requirements 
for ethical approval for the survey, with some requir-
ing approval from an ethics committee as well as writ-
ten informed consent of the residents (or their proxies). 
Confidentiality of the data was ensured by the use of 
a unique, coded survey identification number for each 
LTCF and for each resident.
Results
Participation
In total, 3,052 LTCFs with 181,462 eligible residents 
from 24 EU/EEA countries participated in the survey. 
After adjustment for over-representation of countries 
contributing to the survey with more than the recom-
mended number of residents, 102,301 eligible residents 
from 1,788 LTCFs remained in the dataset used for 
this analysis (Table 1). Data from the United Kingdom 
(UK) were reported separately for three administra-
tions: UK-Northern Ireland, UK-Scotland and UK-Wales. 
UK-England did not participate in the survey. The Czech 
Republic only provided institutional-level data for nine 
LTCFs and was therefore excluded in the antimicrobial 
use and resident data analysis.
Antimicrobial use and resident data
On the day of the survey, 5,035 residents received at 
least one antimicrobial agent, resulting in a crude, 
pooled prevalence of antimicrobial use of 4.9% (95% 
CI: 4.8 to 5.1). The mean antimicrobial use prevalence 
of LTCFs was 5.8% and the median was 3.6% (inter-
quartile range (IQR): 0.0–8.5) (Table 1).
Detailed information on antimicrobial prescribing 
was provided for 5,006 residents (i.e. all participat-
ing countries except Cyprus and the Czech Republic). 
The median age of residents was 85 years; 65.7% were 
female and 93.8% received one antimicrobial agent, 
while 5.8% received two and 0.4% received more 
than two. In total, 5,344 antimicrobial agents were 
reported to have been given on the day of the survey, 
an average of 1.07 antimicrobial agents per resident. 
Antimicrobials were mainly administered orally (88.1%) 
The parenteral route (intramuscular or intravenous) 
was used for 10.9% of prescribed antimicrobials and 
nasal or rectal administration route was reported for 
only 0.7% of prescribed antimicrobials.
Antimicrobials were most frequently prescribed within 
the same LTCF (77.9%), followed by an acute care hos-
pital (12.9%) or another location (5.1%), with no data 
provided for the remaining 4.2%. The indication was 
reported as treatment for 69.5% and prophylaxis for 
29.4% of prescribed antimicrobials, and indication was 
missing for the remaining 1.1%. An end or review date 
for the prescription was documented for 64.6% of pre-
scribed antimicrobials and was higher for treatment 
(81.6%) than for prophylaxis (26.2%).  Figure 1  shows 
the distribution of antimicrobial use by indication and 
common site of infection for the EU/EEA overall and for 
each country.
Overall, the urinary tract was the most common body 
site for which antimicrobials were prescribed (46.1%), 
followed by respiratory tract (29.4%) and skin or wound 
(12.6%). Combined, these sites accounted for 88.0% of 
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all antimicrobial prescriptions. When stratified by indi-
cation, the most common sites for antimicrobial treat-
ment were the respiratory tract (37.2%), urinary tract 
(34.4%), skin or wound (15.8%) and gastrointestinal 
tract (2.8%). For prophylaxis, the urinary tract was the 
most common body site (74.0%), followed by respira-
tory tract (11.3%), skin or wound (4.8%), another non-
specified body site (3.4%) and gastrointestinal tract 
(2.4%).
Antibacterials for systemic use (ATC J01) accounted for 
95.4% of all antimicrobial prescriptions. Other antimi-
crobial groups accounted for the remaining 4.6%, i.e. 
nitroimidazole derivatives (P01AB, 1.5%), intestinal 
anti-infectives–antibiotics (A07AA, 1.3%), antimycotics 
for systemic use (J02, 1.2%), antimycobacterials for 
treatment of tuberculosis (J04A, 0.5%) and antifungals 
for systemic use (D01B, 0.2%).
In total, 5,098 prescriptions of antibacterials for sys-
temic use (ATC J01) were reported. Within this group, 
the most frequently reported subgroups were: beta-
lactam antibacterials, penicillins (J01C: 30.2%), other 
antibacterials (J01X: 18.6%), quinolones (J01M: 14.9%), 
sulfonamides and trimethoprim (J01E: 13.3%) and other 
beta-lactams (J01D: 12.6%). Other groups accounted 
for the remaining 10.4% of antibacterials for systemic 
use.  Figure 2  shows the distribution of antibacterials 
for systemic use by indication (prophylaxis or treat-
ment) and by country.
For prophylaxis of urinary tract infection (UTI), the 
most frequently used antimicrobial agents were tri-
methoprim (J01EA01: 29.7%), nitrofurantoin (J01XE01: 
27.0%), methenamine (J01XX05: 11.6%), cefalexin 
(J01DB01: 6.1%) and fosfomycin (J01XX01: 5.9%); these 
accounted for 81.8% of all antimicrobials used for 
prophylaxis of UTI.
The LTCF and LTCF population characteristics associ-
ated with prevalence of antimicrobial use, as identi-
fied in the multivariable linear regression analysis, 
are presented in  Table 2. The regression model indi-
cated that LTCF and LTCF population characteristics 
only explained 19% of the variance in the prevalence 
of antimicrobial use (R2  =  0.1889). Prevalence of 
antimicrobial use was significantly higher in mixed 
LTCFs, as well as in LTCFs with less than 65 beds. For the 
demographic characteristics, for one percent increase 
in the proportion of male residents the prevalence of 
antimicrobial use increased by 7%. For one percent 
increase in the proportion of residents over 85 years 
of age, the prevalence of antimicrobial use increased 
by 5%. For the care load indicators and risk factors, 
the most significant increases in antimicrobial use 
prevalence were associated with the proportion of 
residents with a vascular catheter and with surgery 
in the previous 30 days; for one percent increase in 
the proportion of these risk factors, the prevalence 
increased by 26% and 20%, respectively.
Antimicrobial stewardship indicators
Of the antimicrobial stewardship indicators reported at 
LTCF level, the most common was ‘written guidelines 
for appropriate antimicrobial use in the LTCF’ (39.4%). 
Annual regular training on appropriate antimicrobial 
prescribing was reported by 20.7% of LTCFs included 
in the sample. Having a ‘restrictive list’ of antimicrobi-
als was reported by 24.0% of LTCFs; the antimicrobials 
most commonly restricted were carbapenems (J01DH, 
70.1%), parenteral vancomycin (J01XA01, 63.7%), all 
intravenously administered antibiotics (53.9%), gly-
copeptides (J01XA, 53.9%), third-generation cephalo-
sporins (J01DD, 45.3%), ‘broad-spectrum antibiotics’ 
(41.9%), fluoroquinolones (J01MA, 32.8%) and mupi-
rocin (D06AX09 and R01AX06, 21.3%) (Table 3).
Discussion
This study examined antimicrobial prescribing in LTCFs 
in 24 EU/EEA countries. The crude prevalence of resi-
dents receiving at least one antimicrobial agent was 
4.9%; the majority of antimicrobials being adminis-
tered orally. Antimicrobials were more frequently pre-
scribed for the treatment of an infection, while almost 
one third were given as prophylaxis. The crude prev-
alence of antimicrobial use in this survey in 2016–17 
was similar to that reported in previous similar HALT 
surveys from 2010 (4.3%) and 2013 (4.4%) [19,20]. UTIs 
and respiratory tract infections were the main indica-
tions for antimicrobial use, both for treatment or as 
prophylaxis. This and previous similar surveys in the 
EU/EEA consistently show large variations of antimicro-
bial prescribing practices in LTCFs, across and within 
participating countries [19-21]. The prevalence of resi-
dents receiving antimicrobials for prophylaxis also var-
ied largely across countries. In Denmark and Finland, 
prophylaxis was reported more frequently than treat-
ment, confirming the high proportion of prophylaxis 
reported in previous surveys from these countries 
[19,20].
The most commonly prescribed antimicrobials were: 
penicillins, other antibacterials, quinolones, sulfona-
mides and trimethoprim, and other beta-lactams. 
Penicillins, other antibacterials and quinolones were 
also the most frequently prescribed antimicrobi-
als in both the 2010 and 2013 HALT surveys. For UTI 
prophylaxis, other antibacterials, sulfonamides and 
trimethoprim, and penicillins were the most commonly 
prescribed antimicrobials, as in both the 2010 and 
2013 surveys [19,20].
There is variation within the EU/EEA in what is consid-
ered long-term care with regard to sheltered housing, 
length of stay and range of beneficiaries, as well as 
an absence of a clear division between medical and 
social services [22]. To enhance comparability, we 
only included nursing homes, residential homes and 
mixed LTCFs in this analysis. Despite this, we noted dif-
ferences in the case-mix of resident populations. For 
example, Spain reported that post-acute care residents 
were commonly included to the surveyed population. In 
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the Netherlands, the level of care provided in the LTCFs 
covers residents that previously would have often been 
admitted to a hospital. Therefore, such differences in 
the definition of long-term care might partially explain 
a high prevalence of antimicrobial use in some EU/EEA 
countries. The large variation between LTCFs in the 
prevalence of residents with a vascular catheter or with 
previous surgery is an indication that some of the par-
ticipating LTCFs could, in fact, be step-down facilities 
with a very different resident case-mix than an average 
nursing home.
Large differences were observed in the prevalence of 
care load indicators and risk factors between coun-
tries, as well as within each country (unpublished 
data). Our multivariable analysis showed that several 
of these indicators and risk factors were independently 
and positively associated with prevalence of antimi-
crobial use. However, our model that took into account 
LTCF characteristics and resident characteristics, 
including care load and risk factors, only explained 
19% of the variation in the prevalence of antimicrobial 
use in LTCFs in EU/EEA countries. This suggests that 
other factors, such as national or regional regulations 
on antimicrobial use, as well as local habits and pre-
scriber preferences and practices, have a larger impact 
than characteristics of the residents’ population [23]. 
In this survey, prophylaxis of UTI was a frequent indica-
tion for antimicrobial use in LTCFs, remaining the most 
common indication in several countries and showing no 
significant decline since the HALT surveys performed in 
2010 or 2013 [19,20]. Although evidence suggests that 
long-term antimicrobials for prophylaxis may reduce 
the risk of recurrence of UTIs in women [24], this ben-
efit diminishes immediately on cessation of antimicro-
bial use and, more importantly, is associated with a 
large increase in the proportion of antibiotic-resistant 
bacteria isolated from urine and faeces. Therefore, the 
practice of prescribing antimicrobials for prophylaxis 
of UTI should be carefully evaluated, and more studies 
about the effectiveness of prophylaxis of UTIs in the 
LTCF populations may be needed, depending also on 
the chosen antimicrobial. For example, the character-
istics of methenamine (ATC J01XX05) are very different 
from that of other antimicrobials commonly prescribed 
for prophylaxis of UTI [25,26].
Information on antimicrobial stewardship indica-
tors was collected to describe the resources avail-
able in LTCFs to support rational use of antimicrobials. 
Documentation of the end or review date for the pre-
scription in the residents’ notes is an indicator of the 
quality of antimicrobial prescription, and this end or 
review date was documented for almost two out of 
three prescriptions overall; however, end or review 
dates were only reported in one out of four prescrip-
tions for prophylaxis. Other antimicrobial stewardship 
indicators, such as guidelines for appropriate use, 
were reported by a small proportion of LTCFs in the EU/
EEA. Some countries, such as France, Germany, the 
Netherlands and Norway, reported the dissemination 
of national guidelines and Norway and the Netherlands 
reported that the guidelines were specific for the 
elderly patient population. The antimicrobial steward-
ship indicator data in this survey were comparable 
with that from previous similar surveys, which indicate 
that improvements in antimicrobial stewardship are 
urgently needed in LTCFs in the EU/EEA [16,27].
The strengths of this survey include the use of a stand-
ardised protocol across all participating LTCFs, the col-
lection of detailed data on the LTCF characteristics and 
antimicrobial stewardship practices and the inclusion 
of a wide variety of LTCF residents and data on their 
antimicrobial use. The survey is characterised by broad 
participation and a very large sample size, providing a 
good overall picture of antimicrobial use in LTCFs in the 
EU/EEA, with meaningful benchmarks for participating 
countries and LTCFs. Considering the participation and 
representativeness of the current survey, it is impor-
tant to note that the overall number of participating 
countries increased from the previous HALT survey in 
2013; in addition, the number of participating LTCFs 
increased progressively between the first survey in 
2010 and this iteration in 2016–17. Increasing partici-
pation remains important, as repeating the survey at 
European level with regular time intervals can encour-
age countries to develop their own national surveil-
lance network for LTCFs, as has been the case in the 
Netherlands, Norway and Sweden, for example [28-30].
One limitation of this survey was its cross-sectional 
design, as a survey conducted on one single day can 
be prone to variation. Nevertheless, this methodology 
was chosen because of its feasibility when applied in 
settings with limited resources for surveillance and for 
infection prevention and control, such as LTCFs. Another 
limitation was that country representativeness was not 
optimal in all countries and convenience sampling was 
often used; both of these factors add to the limitations 
for inter-country comparisons. An additional limitation 
of our analysis was the large number of LTCFs that did 
not report any resident with at least one antimicrobial 
agent on the day of the survey, which may be another 
consequence of the differences between participating 
LTCFs and might warrant more sophisticated statistical 
methods to take this into account in future analyses.
In conclusion, this third PPS provided overall repre-
sentative data on antimicrobial use in LTCFs across the 
EU/EEA countries, and demonstrated that continued 
surveillance for antibiotic use and stewardship prac-
tices in LTCFs remains critical. The survey data allow for 
identifying targets for future antimicrobial stewardship 
interventions, specifically in LTCFs; for example focus-
ing on prophylaxis for UTIs, following up on the impact 
of interventions and, ultimately, contributing to the 
promotion of prudent use of antimicrobials in LTCFs.
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